BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 9225826)

  • 1. Extrapancreatic action of truncated glucagon-like peptide-I in Otsuka Long-Evans Tokushima Fatty rats, an animal model for non-insulin-dependent diabetes mellitus.
    Mizuno A; Kuwajima M; Ishida K; Noma Y; Murakami T; Tateishi K; Sato I; Shima K
    Metabolism; 1997 Jul; 46(7):745-9. PubMed ID: 9225826
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients.
    Vilsbøll T; Krarup T; Madsbad S; Holst JJ
    Diabetologia; 2002 Aug; 45(8):1111-9. PubMed ID: 12189441
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Subcutaneous injection of the incretin hormone glucagon-like peptide 1 abolishes postprandial glycemia in NIDDM.
    Gutniak MK; Linde B; Holst JJ; Efendić S
    Diabetes Care; 1994 Sep; 17(9):1039-44. PubMed ID: 7988303
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients.
    Toft-Nielsen MB; Madsbad S; Holst JJ
    Diabetes Care; 1999 Jul; 22(7):1137-43. PubMed ID: 10388979
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The short half-life of glucagon-like peptide-1 in plasma does not reflect its long-lasting beneficial effects.
    Hui H; Farilla L; Merkel P; Perfetti R
    Eur J Endocrinol; 2002 Jun; 146(6):863-9. PubMed ID: 12039708
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glucagon-like peptide 1 improves the ability of the beta-cell to sense and respond to glucose in subjects with impaired glucose tolerance.
    Byrne MM; Gliem K; Wank U; Arnold R; Katschinski M; Polonsky KS; Göke B
    Diabetes; 1998 Aug; 47(8):1259-65. PubMed ID: 9703326
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Changes in islet capillary angioarchitecture coincide with impaired B-cell function but not with insulin resistance in male Otsuka-Long-Evans-Tokushima fatty rats: dimorphism of the diabetic phenotype at an advanced age.
    Mizuno A; Noma Y; Kuwajima M; Murakami T; Zhu M; Shima K
    Metabolism; 1999 Apr; 48(4):477-83. PubMed ID: 10206441
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma glucagon responses to insulin-induced hypoglycemia and arginine in spontaneous non-insulin-dependent diabetes mellitus (NIDDM) rats, Otsuka Long Evans Tokushima Fatty (OLETF) strain.
    Ishida K; Mizuno A; Sano T; Shi K; Shima K
    Acta Endocrinol (Copenh); 1993 Dec; 129(6):585-93. PubMed ID: 8109192
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glucagon-like peptide I enhances the insulinotropic effect of glibenclamide in NIDDM patients and in the perfused rat pancreas.
    Gutniak MK; Juntti-Berggren L; Hellström PM; Guenifi A; Holst JJ; Efendic S
    Diabetes Care; 1996 Aug; 19(8):857-63. PubMed ID: 8842604
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers.
    Nauck MA; Heimesaat MM; Behle K; Holst JJ; Nauck MS; Ritzel R; Hüfner M; Schmiegel WH
    J Clin Endocrinol Metab; 2002 Mar; 87(3):1239-46. PubMed ID: 11889194
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential effects of acute and extended infusions of glucagon-like peptide-1 on first- and second-phase insulin secretion in diabetic and nondiabetic humans.
    Quddusi S; Vahl TP; Hanson K; Prigeon RL; D'Alessio DA
    Diabetes Care; 2003 Mar; 26(3):791-8. PubMed ID: 12610039
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glucagon-like peptide-1 augments insulin-mediated glucose uptake in the obese state.
    Egan JM; Meneilly GS; Habener JF; Elahi D
    J Clin Endocrinol Metab; 2002 Aug; 87(8):3768-73. PubMed ID: 12161508
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Which is the primary etiologic event in Otsuka Long-Evans Tokushima Fatty rats, a model of spontaneous non-insulin-dependent diabetes mellitus, insulin resistance, or impaired insulin secretion?
    Ishida K; Mizuno A; Min Z; Sano T; Shima K
    Metabolism; 1995 Jul; 44(7):940-5. PubMed ID: 7616855
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glucagon-like peptide 1 increases insulin sensitivity in depancreatized dogs.
    Sandhu H; Wiesenthal SR; MacDonald PE; McCall RH; Tchipashvili V; Rashid S; Satkunarajah M; Irwin DM; Shi ZQ; Brubaker PL; Wheeler MB; Vranic M; Efendic S; Giacca A
    Diabetes; 1999 May; 48(5):1045-53. PubMed ID: 10331409
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of beta-cell secretory capacity using glucagon-like peptide 1.
    Vilsbøll T; Toft-Nielsen MB; Krarup T; Madsbad S; Dinesen B; Holst JJ
    Diabetes Care; 2000 Jun; 23(6):807-12. PubMed ID: 10841001
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gut incretin hormones in identical twins discordant for non-insulin-dependent diabetes mellitus (NIDDM)--evidence for decreased glucagon-like peptide 1 secretion during oral glucose ingestion in NIDDM twins.
    Vaag AA; Holst JJ; Vølund A; Beck-Nielsen HB
    Eur J Endocrinol; 1996 Oct; 135(4):425-32. PubMed ID: 8921824
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Determinants of the effectiveness of glucagon-like peptide-1 in type 2 diabetes.
    Toft-Nielsen MB; Madsbad S; Holst JJ
    J Clin Endocrinol Metab; 2001 Aug; 86(8):3853-60. PubMed ID: 11502823
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glucagon-like peptide 1 increases mass but not frequency or orderliness of pulsatile insulin secretion.
    Pørksen N; Grøfte B; Nyholm B; Holst JJ; Pincus SM; Veldhuis JD; Schmitz O; Butler PC
    Diabetes; 1998 Jan; 47(1):45-9. PubMed ID: 9421373
    [TBL] [Abstract][Full Text] [Related]  

  • 19. No reactive hypoglycaemia in Type 2 diabetic patients after subcutaneous administration of GLP-1 and intravenous glucose.
    Vilsbøll T; Krarup T; Madsbad S; Holst JJ
    Diabet Med; 2001 Feb; 18(2):144-9. PubMed ID: 11251679
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The pathophysiology of diabetes involves a defective amplification of the late-phase insulin response to glucose by glucose-dependent insulinotropic polypeptide-regardless of etiology and phenotype.
    Vilsbøll T; Knop FK; Krarup T; Johansen A; Madsbad S; Larsen S; Hansen T; Pedersen O; Holst JJ
    J Clin Endocrinol Metab; 2003 Oct; 88(10):4897-903. PubMed ID: 14557471
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.